{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:20:47Z","timestamp":1790886047473,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Nontuberculous mycobacterial (NTM) pulmonary disease prevalence is increasing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine the association between the use of inhaled corticosteroids and the likelihood of NTM pulmonary infection among individuals with treated airway disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a case\u2013control study of subjects with airway disease with and without NTM pulmonary infection (based on mycobacterial respiratory cultures) between 2000 and 2010 in northern California. We quantified the use of inhaled corticosteroids, other airway disease medications, and healthcare use within 6 months of NTM pulmonary infection identification. We used 1:10 case\u2013control matching and conditional logistic regression to evaluate the association between the duration and cumulative dosage of inhaled corticosteroid use and NTM pulmonary infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 248 cases with NTM pulmonary infection with an estimated rate of 16.4 cases per 10,000 subjects treated for airway disease. The median interval between treated airway disease cohort entry (defined as date of patient filling the third airway disease treatment prescription) and NTM case identification was 1,217 days. Compared with control subjects, subjects with NTM pulmonary infection were more likely to use airway disease medications including systemic steroids; they were also more likely to use health care. Any inhaled corticosteroids use between 120 days and 2 years before cohort entry was associated with substantially increased odds of NTM infection. For example, the adjusted odds ratio for NTM infection among inhaled corticosteroid users in a 2-year interval was 2.51 (95% confidence interval, 1.40\u20134.49; P\u2009&amp;lt;\u20090.01). Increasing cumulative inhaled corticosteroid dose was also associated with greater odds of NTM infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Inhaled corticosteroid use, and particularly high-dose inhaled corticosteroid use, was associated with an increased risk of NTM pulmonary infection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.201804-245oc","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T03:01:48Z","timestamp":1536894108000},"page":"1169-1176","source":"Crossref","is-referenced-by-count":62,"title":["Association Between Inhaled Corticosteroid Use and Pulmonary Nontuberculous Mycobacterial Infection"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6899-9998","authenticated-orcid":false,"given":"Vincent X.","family":"Liu","sequence":"first","affiliation":[{"name":"Division of Research, Kaiser Permanente, Oakland, California"},{"name":"Santa Clara Medical Center, Kaiser Permanente, Santa Clara, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University, Portland, Oregon; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Lu","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husham","family":"Sharifi","sequence":"additional","affiliation":[{"name":"Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hekmat U.","family":"Nasiri","sequence":"additional","affiliation":[{"name":"Santa Clara Medical Center, Kaiser Permanente, Santa Clara, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7231-3813","authenticated-orcid":false,"given":"Stephen J.","family":"Ruoss","sequence":"additional","affiliation":[{"name":"Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,10,1]]},"reference":[{"key":"2026020502194949000_bib1","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1378\/chest.15-0458","article-title":"Pulmonary disease due to nontuberculous mycobacteria: current state and new insights","volume":"148","author":"McShane","year":"2015","journal-title":"Chest"},{"key":"2026020502194949000_bib2","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1164\/rccm.201002-0310OC","article-title":"Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems","volume":"182","author":"Prevots","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502194949000_bib3","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1086\/648443","article-title":"Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology","volume":"49","author":"Cassidy","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2026020502194949000_bib4","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1164\/rccm.201003-0503OC","article-title":"Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease","volume":"182","author":"Winthrop","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502194949000_bib5","doi-asserted-by":"crossref","first-page":"1700037","DOI":"10.1183\/13993003.00037-2017","article-title":"The risk of mycobacterial infections associated with inhaled corticosteroid use","volume":"50","author":"Brode","year":"2017","journal-title":"Eur Respir J"},{"key":"2026020502194949000_bib6","first-page":"19","article-title":"Isolation prevalence of pulmonary nontuberculous mycobacteria in Ontario in 2007","volume":"18","author":"Al Houqani","year":"2011","journal-title":"Can Respir J"},{"key":"2026020502194949000_bib7","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1164\/rccm.201111-2016OC","article-title":"Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries","volume":"185","author":"Adjemian","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502194949000_bib8","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1513\/AnnalsATS.201412-559OC","article-title":"Population-based incidence of pulmonary nontuberculous mycobacterial disease in Oregon 2007 to 2012","volume":"12","author":"Henkle","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"2026020502194949000_bib9","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1164\/rccm.200905-0778OC","article-title":"Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors","volume":"181","author":"Andr\u00e9jak","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502194949000_bib10","doi-asserted-by":"crossref","first-page":"e91879","DOI":"10.1371\/journal.pone.0091879","article-title":"Nontuberculous mycobacterial disease mortality in the United States, 1999-2010: a population-based comparative study","volume":"9","author":"Mirsaeidi","year":"2014","journal-title":"PLoS One"},{"key":"2026020502194949000_bib11","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.rmed.2011.08.004","article-title":"Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease","volume":"105","author":"Mehta","year":"2011","journal-title":"Respir Med"},{"key":"2026020502194949000_bib12","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1513\/AnnalsATS.201503-173OC","article-title":"The burden of pulmonary nontuberculous mycobacterial disease in the United States","volume":"12","author":"Strollo","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"2026020502194949000_bib13","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1183\/09031936.00055010","article-title":"The cost of medical management of pulmonary nontuberculous mycobacterial disease in Ontario, Canada","volume":"37","author":"Leber","year":"2011","journal-title":"Eur Respir J"},{"key":"2026020502194949000_bib14","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1513\/AnnalsATS.201508-524ED","article-title":"Nontuberculous mycobacterial lung disease: time to get a grip!","volume":"12","author":"Thomson","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"2026020502194949000_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1440-1843.2011.02076.x","article-title":"Increased risk of nontuberculous mycobacterial infection in asthmatic patients using long-term inhaled corticosteroid therapy","volume":"17","author":"Hojo","year":"2012","journal-title":"Respirology"},{"key":"2026020502194949000_bib16","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201205-0825OC","article-title":"Environment or host? A case\u2013control study of risk factors for Mycobacterium avium complex lung disease","volume":"186","author":"Dirac","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502194949000_bib17","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1164\/rccm.201208-1432ED","article-title":"Host susceptibility or environmental exposure in Mycobacterium avium complex lung disease: it takes two to tango","volume":"186","author":"Marras","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502194949000_bib18","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"key":"2026020502194949000_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","article-title":"The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide","volume":"177","author":"Wedzicha","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502194949000_bib20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/thoraxjnl-2012-201772","article-title":"Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis","volume":"68","author":"Andr\u00e9jak","year":"2013","journal-title":"Thorax"},{"key":"2026020502194949000_bib21","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.chest.2017.04.167","article-title":"Pharmacotherapy for non-cystic fibrosis bronchiectasis: results from an NTM Info & Research patient survey and the Bronchiectasis and NTM Research Registry","volume":"152","author":"Henkle","year":"2017","journal-title":"Chest"},{"key":"2026020502194949000_bib22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1345\/aph.1L546","article-title":"Comparison of inhaled corticosteroids: an update","volume":"43","author":"Kelly","year":"2009","journal-title":"Ann Pharmacother"},{"key":"2026020502194949000_bib23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502194949000_bib24","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3201\/eid1911.130737","article-title":"Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010","volume":"19","author":"Marras","year":"2013","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"2026020502194949000_bib25","first-page":"CD006829","article-title":"Combined corticosteroid and long-acting \u03b22-agonist in one inhaler versus long-acting \u03b22-agonists for chronic obstructive pulmonary disease","author":"Nannini","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2026020502194949000_bib26","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1183\/09031936.00128914","article-title":"Inhaled corticosteroids in COPD: the clinical evidence","volume":"45","author":"Ernst","year":"2015","journal-title":"Eur Respir J"},{"key":"2026020502194949000_bib27","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJM199906243402502","article-title":"Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease","volume":"340","author":"Niewoehner","year":"1999","journal-title":"N Engl J Med"},{"key":"2026020502194949000_bib28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1378\/chest.115.3.703","article-title":"Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987 to 1995","volume":"115","author":"Van Andel","year":"1999","journal-title":"Chest"},{"key":"2026020502194949000_bib29","first-page":"13","article-title":"Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study","volume":"15","author":"Bourbeau","year":"2008","journal-title":"Can Respir J"},{"key":"2026020502194949000_bib30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1345\/aph.1M481","article-title":"COPD management in primary care: an observational, community pharmacy-based study","volume":"44","author":"Mehuys","year":"2010","journal-title":"Ann Pharmacother"},{"key":"2026020502194949000_bib31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/qjmed\/hcm155","article-title":"The impact of the 2004 NICE guideline and 2003 General Medical Services contract on COPD in primary care in the UK","volume":"101","author":"Smith","year":"2008","journal-title":"QJM"},{"key":"2026020502194949000_bib32","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1056\/NEJMoa032158","article-title":"The nature of small-airway obstruction in chronic obstructive pulmonary disease","volume":"350","author":"Hogg","year":"2004","journal-title":"N Engl J Med"},{"key":"2026020502194949000_bib33","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1164\/rccm.200612-1772OC","article-title":"Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology","volume":"176","author":"Hogg","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502194949000_bib34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1465-9921-13-40","article-title":"Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella pneumoniae in mice","volume":"13","author":"Patterson","year":"2012","journal-title":"Respir Res"},{"key":"2026020502194949000_bib35","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1165\/rcmb.2017-0230OC","article-title":"Whole-blood gene expression in pulmonary nontuberculous mycobacterial infection","volume":"58","author":"Cowman","year":"2018","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026020502194949000_bib36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/COPD.S42366","article-title":"Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis","volume":"8","author":"Yawn","year":"2013","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026020502194949000_bib37","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1136\/thoraxjnl-2012-202872","article-title":"Inhaled corticosteroids in COPD and the risk of serious pneumonia","volume":"68","author":"Suissa","year":"2013","journal-title":"Thorax"},{"key":"2026020502194949000_bib38","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1164\/rccm.201007-1099OC","article-title":"Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases","volume":"183","author":"Brassard","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502194949000_bib39","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/thoraxjnl-2012-203175","article-title":"Use of inhaled corticosteroids and the risk of tuberculosis","volume":"68","author":"Lee","year":"2013","journal-title":"Thorax"},{"key":"2026020502194949000_bib40","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/thx.2008.108027","article-title":"The overlap syndrome of asthma and COPD: what are its features and how important is it?","volume":"64","author":"Gibson","year":"2009","journal-title":"Thorax"},{"key":"2026020502194949000_bib41","doi-asserted-by":"crossref","first-page":"e0150532","DOI":"10.1371\/journal.pone.0150532","article-title":"Bronchiectasis as a comorbidity of chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"11","author":"Du","year":"2016","journal-title":"PLoS One"},{"key":"2026020502194949000_bib42","doi-asserted-by":"crossref","first-page":"e0177931","DOI":"10.1371\/journal.pone.0177931","article-title":"Clinical impact of chronic obstructive pulmonary disease on non-cystic fibrosis bronchiectasis: a study on 1,790 patients from the Spanish Bronchiectasis Historical Registry","volume":"12","author":"De la Rosa","year":"2017","journal-title":"PLoS One"},{"key":"2026020502194949000_bib43","doi-asserted-by":"crossref","first-page":"10961","DOI":"10.1038\/srep10961","article-title":"The existence of bronchiectasis predicts worse prognosis in patients with COPD","volume":"5","author":"Mao","year":"2015","journal-title":"Sci Rep"},{"key":"2026020502194949000_bib44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MCP.0b013e32835d8312","article-title":"Chronic obstructive pulmonary disease and bronchiectasis","volume":"19","author":"Novosad","year":"2013","journal-title":"Curr Opin Pulm Med"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/15\/10\/1169\/66733383\/annalsats_15_10_1169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/15\/10\/1169\/66733383\/annalsats_15_10_1169.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:19:58Z","timestamp":1770275998000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/15\/10\/1169\/8456884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10,1]]},"published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.201804-245oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10]]},"published":{"date-parts":[[2018,10,1]]}}}